Stock Analysis

# Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

### Key Insights

• Zhejiang Xinguang Pharmaceutical's estimated fair value is CN¥9.34 based on Dividend Discount Model
• With CN¥11.05 share price, Zhejiang Xinguang Pharmaceutical appears to be trading close to its estimated fair value
• Industry average of 11,294% suggests Zhejiang Xinguang Pharmaceutical's peers are currently trading at a higher premium to fair value

Today we will run through one way of estimating the intrinsic value of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Zhejiang Xinguang Pharmaceutical

## The Calculation

We have to calculate the value of Zhejiang Xinguang Pharmaceutical slightly differently to other stocks because it is a pharmaceuticals company. In this approach dividends per share (DPS) are used, as free cash flow is difficult to estimate and often not reported by analysts. Unless a company pays out the majority of its FCF as a dividend, this method will typically underestimate the value of the stock. The 'Gordon Growth Model' is used, which simply assumes that dividend payments will continue to increase at a sustainable growth rate forever. The dividend is expected to grow at an annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We then discount this figure to today's value at a cost of equity of 7.4%. Compared to the current share price of CN¥11.1, the company appears around fair value at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

Value Per Share = Expected Dividend Per Share / (Discount Rate - Perpetual Growth Rate)

= CN¥0.5 / (7.4% – 2.9%)

= CN¥9.3

## The Assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Zhejiang Xinguang Pharmaceutical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

### SWOT Analysis for Zhejiang Xinguang Pharmaceutical

Strength
• Currently debt free.
• Dividend is in the top 25% of dividend payers in the market.
Weakness
• Earnings declined over the past year.
• Current share price is above our estimate of fair value.
Opportunity
• 300519's financial characteristics indicate limited near-term opportunities for shareholders.
• Lack of analyst coverage makes it difficult to determine 300519's earnings prospects.
Threat
• Dividends are not covered by earnings and cashflows.

## Looking Ahead:

Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Zhejiang Xinguang Pharmaceutical, there are three important aspects you should assess:

1. Risks: We feel that you should assess the 1 warning sign for Zhejiang Xinguang Pharmaceutical we've flagged before making an investment in the company.
2. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
3. Other Top Analyst Picks: Interested to see what the analysts are thinking? Take a look at our interactive list of analysts' top stock picks to find out what they feel might have an attractive future outlook!

PS. Simply Wall St updates its DCF calculation for every Chinese stock every day, so if you want to find the intrinsic value of any other stock just search here.

### Valuation is complex, but we're helping make it simple.

Find out whether Zhejiang Xinguang Pharmaceutical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

### About SZSE:300519

#### Zhejiang Xinguang Pharmaceutical

Zhejiang Xinguang Pharmaceutical Co., Ltd.

Flawless balance sheet unattractive dividend payer.